Ceribell Tops $29.3M Revenue, Lifts 2026 Guidance to $115M-$117M
CBLL has more than doubled off its 52-week low of $10.85.
Summary
Ceribell posted Q3 2026 revenue of $29.3 million, up 30% from $22.6 million a year ago, with gross margin at 90% versus 88%. It added a record 35 net new accounts to reach 747 active accounts and logged double-digit same-store utilization growth. The company raised full-year 2026 revenue guidance to $115 million to $117 million, roughly 29% to 31% growth, and said the range excludes material contribution from neonate, pediatric or delirium products. The quarter also brought FDA 510(k) clearance for Quantitative EEG Trending and Amplitude-Integrated EEG Analysis and the full commercial launch of delirium monitoring, following the pilot announcement on November 2. Losses widened: net loss was $21.4 million, or $0.55 per share, versus $13.5 million a year earlier, and adjusted EBITDA loss grew to $12.1 million from $9.2 million as operating expenses rose 36% on commercial buildout and R&D. Cash and marketable securities stood at $117.5 million at quarter end, with a new credit facility providing up to $60 million committed plus $25 million uncommitted. The stock sits near its 52-week high, so the guidance raise and 90% margin are the numbers that matter for the tape.
At the time of this announcement, CBLL was trading at $28.27 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.1B. The 52-week trading range was $10.85 to $28.89. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.